Shanghai Ruotuo Biotechnology

Shanghai Ruotuo Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapeutics, particularly antibody-drug conjugates (ADCs) and bispecific antibodies. Established as a joint venture between Anwita Biosciences and Shanghai Junshi Biosciences, the company leverages its proprietary ADC development platform, monoclonal/bispecific antibody discovery platform, and Linker-Payload technology platform. Its lead clinical candidate, RT023, is a first-in-class bispecific ADC targeting CEACAM5 and EGFR, currently being evaluated in Phase 1/2 clinical trials for advanced malignant solid tumors, including colorectal cancer. Additionally, the company is advancing preclinical programs, including anti-EGFR/HER3 bispecific ADCs and novel fusion proteins, to address tumor heterogeneity and drug resistance.